8-K: DaVita Inc. Reports Mixed Q4 Results, Cites Resilience Amidst External Challenges

DaVita Inc. announced its fourth quarter and full year 2023 financial results, highlighting the company's resilience and strategic investments despite external challenges.

Summary

• DaVita Inc. reported consolidated revenues of $3.146 billion for the fourth quarter of 2023 and $12.140 billion for the full year.
• Operating income for the quarter was $390 million, with an adjusted operating income of $415 million.
• For the full year, operating income reached $1.603 billion, and adjusted operating income was $1.734 billion.
• Diluted earnings per share from continuing operations were $1.62 for the quarter and $7.42 for the year, while adjusted diluted earnings per share were $1.87 and $8.47, respectively.
• Operating cash flow was $485 million for the quarter and $2.059 billion for the year, with free cash flow at $258 million and $1.236 billion, respectively.
• The company repurchased 2,903,832 shares of its common stock at an average price of $97.82 per share during the quarter.
• U.S. dialysis treatments totaled 7,254,559 for the quarter, averaging 92,533 treatments per day, a slight increase of 0.04% compared to the previous quarter.
• Normalized non-acquired treatment growth was 0.7% compared to the fourth quarter of 2022.
• The company incurred $31.8 million in charges for U.S. dialysis center closures during the quarter and $99.1 million for the full year.
• A non-cash goodwill charge of $26.1 million was recognized in the transplant software business.
• DaVita provided dialysis services to approximately 250,200 patients at 3,042 outpatient dialysis centers as of December 31, 2023.
• The company had approximately 58,000 patients in risk-based integrated care arrangements, representing approximately $4.6 billion in annualized medical spend.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company's resilience and strategic investments, but tempered by the negative impacts of center closures, goodwill impairment, and decreased net income. The forward-looking guidance is positive but includes significant risks and uncertainties.

Positives

• DaVita's financial performance in 2023 demonstrated the resilience of its business.
• The company is entering 2024 with more confidence than it has had since the start of COVID in 2020.
• The company saw a net increase in shared savings recognized on value-based care arrangements.
• DaVita has a strong operating cash flow of $485 million for the quarter and $2.059 billion for the year.
• The company has a strong free cash flow of $258 million for the quarter and $1.236 billion for the year.
• The company has been actively repurchasing shares, indicating confidence in its value.

Negatives

• The company incurred significant charges for U.S. dialysis center closures, totaling $31.8 million for the quarter and $99.1 million for the year.
• A non-cash goodwill impairment charge of $26.1 million was recognized in the transplant software business.
• The company experienced increased patient care costs per treatment due to various factors including compensation and pharmaceutical costs.
• General and administrative expenses increased due to seasonal factors and increased contributions to the charitable foundation.
• The company experienced a decrease in net income from continuing operations compared to the previous quarter.

Risks

• The company faces risks related to macroeconomic conditions, global events, and the ongoing impact of the COVID-19 pandemic.
• There are risks associated with potential changes in laws, regulations, and healthcare policies.
• The company faces challenges in attracting and retaining teammates in a competitive labor market.
• There are risks related to the implementation of integrated kidney care and value-based care initiatives.
• The company is exposed to risks related to government payment rates and potential changes in pharmaceutical pricing.
• There are risks associated with increased competition from other dialysis providers and new entrants in the market.
• The company faces risks related to its ability to generate sufficient cash flow to service its debt and fund other liquidity needs.
• There are risks related to the use of accounting estimates and potential impairment of assets.
• The company faces risks related to environmental, social, and governance (ESG) matters.

Future Outlook

DaVita provided 2024 guidance for adjusted operating income between $1.825 billion and $1.975 billion, adjusted diluted net income per share between $8.70 and $9.80, and free cash flow between $900 million and $1.150 billion. The company noted that these forward-looking measures involve significant risks and uncertainties.

Management Comments

• Javier Rodriguez, CEO of DaVita Inc., stated that the 2023 financial performance highlighted the resilience of the business.
• He also mentioned that the external challenges of recent years ultimately made the company stronger.
• Management believes that the company is well positioned for the years ahead with continued investment in teammates, systems, and capabilities.
• The company enters 2024 with more confidence than it has had since the start of COVID in 2020.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the dialysis industry, including the shift towards value-based care and integrated kidney care models. The company's focus on cost savings and strategic reviews of clinic capacity aligns with industry trends to optimize operations and adapt to changing patient needs and market conditions. The company is also facing increased competition and potential impacts from new technologies and treatments.

Comparison to Industry Standards

• DaVita's performance is being compared to other major dialysis providers such as Fresenius Medical Care, which also faces similar challenges related to reimbursement rates, labor costs, and the shift to value-based care.
• The company's focus on integrated kidney care is in line with industry trends to improve patient outcomes and reduce overall healthcare costs, similar to initiatives being pursued by other large healthcare providers.
• The reported treatment volumes and revenue per treatment are key metrics used to benchmark DaVita's performance against its peers in the dialysis industry.
• The company's share repurchase program is a common strategy among publicly traded companies in the healthcare sector to enhance shareholder value, similar to actions taken by other companies in the industry.
• The closure of dialysis centers is a common practice in the industry as companies optimize their networks and adapt to changing patient demographics and treatment preferences, similar to actions taken by other dialysis providers.

Stakeholder Impact

• Shareholders may be impacted by the share repurchases and the company's financial performance.
• Employees may be impacted by cost savings initiatives and changes in the labor market.
• Patients may be impacted by changes in center locations and the implementation of integrated care programs.
• Suppliers may be impacted by changes in procurement strategies.
• Creditors may be impacted by the company's debt levels and cash flow.

Next Steps

• The company will hold a conference call to discuss the results on February 13, 2024.
• DaVita will continue to implement its cost savings initiatives.
• The company will continue to monitor and respond to macroeconomic and marketplace conditions.
• DaVita will continue to focus on integrated kidney care and value-based care initiatives.

Key Dates

Keywords

dialysis, healthcare, renal care, integrated kidney care, value-based care, financial results, operating income, earnings per share, cash flow, share repurchases, center closures, goodwill impairment